A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Exclusion Criteria

• •• No more than 5 cytotoxic regimens
• •* Previous allogeneic or autologous stem cell transplantation permitted
• •* ≥ 3 weeks delay from prior cytotoxic chemotherapy or radiation therapy
• •* ≥ 2 week delay from prior biologic therapies including hematopoietic growth factors and vidaza or decitabine
• •* If using Hydroxyurea, steroids, tyrosine kinase/src kinase inhibitors, arsenic, interferon for count control, must be off therapy for ≥ 48 hours prior to beginning PD 0332991
• •* No concomitant use of potent CYP450 3A4 inhibitors (e.g. triazole antifungal agents) or inducers (e.g. omperazole, dilantin, dexamethasone) within 7 days prior to beginning PD 0332991